Test Code HPVS HPV Self Collection
EHR Test Codes
| Test Code | Test Name | |
| Atlas | HPVS | HPV High Risk w/Genotype Self Collection |
| Cerner | HPVS | HPV High Risk with Genotype Self Collection |
Specimen Requirements
Preparation of Patient:
Who is self-collection appropriate for?
-
HPV self- collections is intended for people who face barriers to clinical collected screening and is offered as an alternative when traditional methods don’t work.
-
Self-collected vaginal specimens are acceptable for primary HPV screening of asymptomatic average risk individuals.
-
Patient must be 25 – 65 years old
Specimen must be collected in a healthcare setting, testing is not available for at home collection. Provide patient with a labeled Evalyn brush and the accompanying collection instructions.
Click for Collection Instructions
Container Type:
Patient:
Evalyn Brush
MHC Laboratory:
ThinPrep® PreservCyt® Solution
Or
Aliquot Transfer Tube
Specimen Type:
Vaginal self-collection using Evalyn Brush into PreservCyt Solution
Specimen Volume:
2.0 mL minimum 1.0 mL
Specimen Handling/Transport:
Label Evalyn brush with patient’s legal name (last, first), patient’s date of birth, specimen source, and collection date/time. Cap tightly and transport ambient room temperature or refrigerated 2 - 30°C to laboratory within 72 hours of collection.
MHC Laboratory Instructions:
- Carefully uncap the ThinPrep® PreservCyt® Solution vial.
- Remove the pink cap from the Evalyn Brush. Press the pink plunger down until it clicks into place to expose the white brush. (do not touch exposed end white brush)
- Hold the vial with one hand then with other hand place the white brush into the vial so the bristles are fully immersed in the medium and the wings are past the opening of the vial.
- Holding the vial, vigorously plunge the brush, smashing the white brush against the bottom and interior wall of the vial 10 times to maximize sample release.
- Remove the white brush carefully drawing the brush up along the inner wall of the via until thebrush is no longer submerged in the medium. Hold the brush against the inner vial wall to drain fluid off the brush.
- Re-cap the vial and tighten until the lines on the cap and vial meet or slightly overlap and store upright. Discard the evalyn brush.
- Label vial with patient’s legal name (last, first), patient’s date of birth, specimen source, and collection date/time.
- Transport aliquot specimen ambient room temperature or refrigerated 2 - 30°C.
Aliquot for instrument processing:
- Using a sterile pipette, aliquot 2 mL minimum 1 mL into aliquot transfer tube. Cap tightly.
- Label collection tube with patient’s legal name (last, first), patient’s date of birth, specimen source, and collection date/time.
- Transport aliquot specimen ambient room temperature or refrigerated 2 - 30°C.
Specimen Stability/Storage:
Evalyn brush devices are stable ambient room temperature for up to 72 hours. Specimens suspended in ThinPrep® PreservCyt® Solution may be stored at 2-30°C for up to 3 months after the date of collection.
Performing Laboratory
Munson Medical Center Laboratories
Microbiology Department
Test Priority, Frequency, & Turnaround Time
Priority:
Non-emergent
Frequency:
Monday through Friday
Turnaround Time:
0 - 3 days
Methodology
RT-PCR
Reporting
Reference Range:
HPV 16 Negative
HPV 18 Negative
HPV Other Negative
Interpretive Data:
Other high risk HPV types include 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Test preformed on the Roche Cobas 6800 by RT-PCR, a Nucleic Acid Amplification method. Testing performed by Munson Healthcare, Traverse City, MI 49684
Critical Decision:
None
Clinical Significance
Clinical management for self-collected vaginal specimens by test result:
|
Result |
Clinical Management |
|
HPV-negative |
Repeat HPV testing in 3 years |
|
HPV 16 or 18 |
Colposcopy with collection of cytology and biopsies |
|
HPV 45, 33/58, 31, 52, 35/39/68, 51 or other pooled HPV types |
Clinician-collected sample for cytology |
Persistent infection with these high risk HPV genotypes is the central cause of cervical cancer and its precursor cervical intraepithelial neoplasia (CIN) Sexually transmitted infections with HPV is extremely common, with estimates of up to 75% of all women experiencing exposure to HPV at some point. However, most infections clear within 1-2 years. Most cervical cancers and deaths from cervical cancer can be prevented through early detection of pre-cancerous lesions in the cervix, leading to timely treatment.
Cytological abnormalities are primarily due to infection with HPV; however, various inflammatory or sampling variations can result in false positive cytology results.
Nucleic acid (DNA) testing by PCR is a non-invasive method for determining the presence of a cervical HPV infection. Proper implementation of nucleic acid testing for HPV may increase the sensitivity of cervical cancer screening programs by detecting high-risk lesions earlier in women 25 years and older and reducing the need for unnecessary colposcopy and treatment in patients 21 and older with ASC-US cytology.
CPT Code(s)
87621